Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02124603
Other study ID # 041SI
Secondary ID
Status Completed
Phase N/A
First received April 23, 2014
Last updated December 15, 2015
Start date April 2014
Est. completion date October 2014

Study information

Verified date December 2015
Source SIFI SpA
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Observational

Clinical Trial Summary

The purpose of the present study is to elucidate the spectrum of ocular flora and their antimicrobial susceptibility profiles in patients undergoing routine cataract surgery.


Description:

A conjunctival and palpebral swab will executed at least 14 days before routine cataract surgery. Isolates will be identified using standard microbiological protocols. In vitro susceptibility will be determined using a breakpoint minimal inhibitory concentrations. In case of positivity, the swab will be repeated the day of surgery. Topical antibiotic may be used in case of positivity at the discretion of the surgeon. Descriptive statistics will be calculated.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients scheduled for cataract surgery

- Age > 18 years

- Any gender and race

- Willing to sign informed consent

Exclusion Criteria:

- Any antibiotics within 3 months

- Any ocular infection within 3 months

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms

  • Cataract
  • Disorders of the Eye Following Cataract Surgery

Locations

Country Name City State
Italy Casa di Cura Di Stefano Catania

Sponsors (1)

Lead Sponsor Collaborator
SIFI SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive Culture in Subjects Scheduled for Cataract Surgery Number of participants with positive culture at the screening visit At least 14 days before surgery No
Secondary Antibiotic Susceptibility Isolated bacteria were tested for their in vitro susceptibility to commercially available ophthalmic antibiotics by the disk diffusion test and categorized as susceptible, intermediate or resistant. At least 14 days before surgery No
Secondary Eradication Rate Number of participants having positive culture at the screening visit with bacterial eradication before surgery Day of surgery No
See also
  Status Clinical Trial Phase
Recruiting NCT05147233 - OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery Phase 3